产品名称
小鼠抗人IgA抗体，克隆M24A，重链，FITC偶联, clone M24A, Chemicon®, from mouse
biological source
mouse
conjugate
FITC conjugate
antibody form
purified immunoglobulin
antibody product type
secondary antibodies
clone
M24A, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
isotype
IgG1
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Application
FITC偶联的小鼠抗人IgG抗体，克隆M24A，重链经验证可用于ELISA、FC、IF、IH，用于检测人IgA。
研究子类别
片段特异性二抗
片段特异性二抗
研究类别
二抗&对照抗体
二抗&对照抗体
组织切片中表达IgA的细胞的免疫组织学染色。
通过直接免疫荧光鉴定B淋巴细胞上的表面IgA。
ELISA
流式细胞术
最佳工作稀释度必须由最终用户进行确定。
通过直接免疫荧光鉴定B淋巴细胞上的表面IgA。
ELISA
流式细胞术
最佳工作稀释度必须由最终用户进行确定。
Biochem/physiol Actions
该抗体对人免疫球蛋白A重链具有特异性，与完整的人IgM或IgG、κ或λ轻链无交叉反应性
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Physical form
偶联物以溶于含有10 mM叠氮化钠和1 mg/ml牛血清白蛋白的磷酸盐缓冲生理盐水中的形式提供。 对于流式细胞仪，我们建议每次测试使用10 μL偶联物。
Preparation Note
在+4°C环境中避光保存。 不可冷冻。 对于长期使用和储存，请将偶联物等分，在+4°C可储存长达一年。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Jackson S Turner et al.
Nature, 595(7867), 421-425 (2021-05-25)
Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-28-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum
Philip A Mudd et al.
Cell, 185(4), 603-613 (2022-01-14)
SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from
Jackson S Turner et al.
Nature, 596(7870), 109-113 (2021-06-29)
SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-191-5. The dynamics of antibody-secreting plasmablasts and germinal centre B cells induced by these vaccines in humans remain unclear. Here we examined antigen-specific B cell responses in peripheral blood (n = 41) and draining lymph
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
Alsoussi, et al.
Nature, 617, 592-598 (2023)
Joana P Bernardes et al.
Immunity, 53(6), 1296-1314 (2020-12-10)
Temporal resolution of cellular features associated with a severe COVID-19 disease trajectory is needed for understanding skewed immune responses and defining predictors of outcome. Here, we performed a longitudinal multi-omics study using a two-center cohort of 14 patients. We analyzed
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持